Jack L. Wyszomierski Sells 8,768 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski sold 8,768 shares of the firm’s stock in a transaction dated Friday, February 28th. The stock was sold at an average price of $37.80, for a total transaction of $331,430.40. Following the completion of the sale, the director now owns 356,605 shares of the company’s stock, valued at $13,479,669. This trade represents a 2.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Exelixis Stock Up 2.8 %

Shares of NASDAQ:EXEL opened at $38.69 on Friday. The firm has a 50 day moving average of $34.53 and a 200 day moving average of $31.66. The company has a market capitalization of $10.83 billion, a price-to-earnings ratio of 21.86, a price-to-earnings-growth ratio of 1.13 and a beta of 0.53. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $38.72.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, sell-side analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Hedge Funds Weigh In On Exelixis

Large investors have recently added to or reduced their stakes in the company. Coppell Advisory Solutions LLC bought a new stake in shares of Exelixis in the 4th quarter valued at about $25,000. Colonial Trust Co SC lifted its position in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 765 shares during the last quarter. USA Financial Formulas acquired a new stake in Exelixis in the fourth quarter valued at approximately $32,000. Principal Securities Inc. grew its holdings in Exelixis by 62.8% in the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 373 shares during the last quarter. Finally, Kestra Investment Management LLC purchased a new position in Exelixis in the fourth quarter worth $39,000. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on EXEL. UBS Group increased their price objective on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a research report on Tuesday, January 28th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Exelixis in a report on Thursday, February 13th. Stifel Nicolaus boosted their price objective on Exelixis from $30.00 to $36.00 and gave the company a “hold” rating in a report on Wednesday, February 12th. Barclays increased their target price on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Finally, Citigroup boosted their target price on shares of Exelixis from $38.00 to $45.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $37.24.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.